Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Benralizumab Significantly Reduced Oral...
Conference

Benralizumab Significantly Reduced Oral Corticosteroid Dosages And Asthma Exacerbation Rates For Patients With Severe, Uncontrolled Asthma: Results Of The Zonda Phase Iii Trial

Authors

Nair P; Wenzel SE; Rabe K-F; Bourdm A; Lugogo N; Kuna P; Barker P; Sproule S; Ponnarambil S; Goldman M

Volume

195

Publisher

AMER THORACIC SOC

Publication Date

January 1, 2017

Name of conference

International Conference of the American-Thoracic-Society (ATS)

Conference place

Washington, DC

Conference start date

May 19, 2017

Conference end date

May 24, 2017

Conference proceedings

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

ISSN

1073-449X